Table 3.
Univariate and Multivariate analysis for progression free survival (PFS) and overall survival (OS)
| Cox-regression analysis for survival | ||||||||
|---|---|---|---|---|---|---|---|---|
| Univariate (PFS) | Multivariate (PFS) | Univariate (OS) | Multivariate (OS) | |||||
| HR (95%CI) |
p | HR (95%CI) |
p | HR (95%CI) |
P | HR (95%CI) |
p | |
| Sex Female v Male |
0.9 (0.60–1.30) |
0.548 |
1.03 (0.65–1.58) |
0.934 | ||||
| Age categories | ||||||||
| > 75 v 65–75 v < 65 |
1.06 (0.83–1.34) |
0.633 |
1.19 (0.89–1.58) |
0.232 | ||||
| Baseline ECOG PS 31 v 0 |
1.65 (1.36–1.99) |
< 0.0001 |
1.46 (1.19–1.80) |
< 0.0001 |
2.25 (1.74–2.90) |
< 0.0001 |
1.99 (1.52–2.61) |
< 0.0001 |
| Comorbidities 32 v 0–1 |
0.84 (0.57–1.24) |
0.386 |
0.97 (0.62–1.54) |
0.918 | ||||
| Immunotherapy setting III- and beyond v II- v I-line |
0.956 (0.75–1.21) |
0.721 |
1.06 (0.81–1.42) |
0.606 | ||||
| Antibiotics antimicotics | ||||||||
| YES v NOT |
1.5 (0.82–2.73) |
0.187 |
2.24 (1.25–3.99) |
0.006 |
1.48 (0.80–2.73) |
0.201 | ||
| Corticosteroids | ||||||||
| YES v NOT |
2.13 (1.40–3.24) |
< 0.0001 |
1.42 (0.90–2.23) |
0.122 |
2.48 (1.55–3.97) |
< 0.0001 |
1.41 (0.84–2.35) |
0.19 |
| Opioids | ||||||||
| YES v NOT |
1.69 (1.37–2.09) |
< 0.0001 |
1.44 (1.15–1.79) |
0.001 |
1.6 (1.26–2.02) |
< 0.0001 |
1.24 (0.97–1.61) |
0.087 |
| Tumor burden | ||||||||
| High v Low |
1.79 (1.22–2.62) |
0.003 |
1.43 (0.97–2.11) |
0.071 |
2.06 (1.31–3.24) |
0.002 |
1.58 (0.98–2.52) |
0.057 |
mPFS median progression free survival, mOS median overall survival, HR hazard ratio, p p value. In bold p ≤ 0.05